Orchestra BioMed Holdings, Inc.·4

May 19, 8:00 AM ET

Hochman David P 4

Research Summary

AI-generated summary

Updated

Orchestra BioMed (OBIO) CEO David P. Hochman Buys 5,000 Shares

What Happened

  • David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), purchased 5,000 shares of OBIO stock in an open-market transaction on May 15, 2026. The reported weighted-average price was $3.77 per share for a total cost of approximately $18,850. This was a purchase (insider buy), which many investors view as more informative than routine sales.

Key Details

  • Transaction date: 2026-05-15 (reported on Form 4 filed 2026-05-19).
  • Price: weighted average $3.77; actual trades ranged from $3.75 to $3.79 (footnote indicates breakdown available on request).
  • Shares acquired: 5,000 (total value ≈ $18,850).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Filing timeliness: Form 4 was filed on 2026-05-19; this falls within the usual two-business-day reporting window for a May 15 transaction, so the filing appears timely.
  • Remarks/role: Reporting person is CEO and Chairperson (per filing remarks).
  • Footnote: The reported price is a weighted average; the filer will provide per-trade breakdown to the issuer, shareholders, or SEC staff upon request.

Context

  • This was a straight open-market purchase (code P). Insider purchases can signal confidence but are not proof of future performance; the purchase size here (~$19k) is modest relative to many insider trades. No options, awards, gifts, or tax-withholding transactions were reported in this filing.